Literature DB >> 8474168

Simian immunodeficiency virus RNA is efficiently encapsidated by human immunodeficiency virus type 1 particles.

T A Rizvi1, A T Panganiban.   

Abstract

Packaging of retroviral RNA is attained through the specific recognition of a cis-acting encapsidation site (located near the 5' end of the viral RNA) by components of the Gag precursor protein. Human immunodeficiency virus type 1 (HIV-1) and simian immunodeficiency virus (SIV) are two lentiviruses that lack apparent sequence similarity in their putative encapsidation regions. We used SIV vectors to determine whether HIV-1 particles can recognize the SIV encapsidation site and functionally propagate SIV nucleic acid. SIV nucleic acid was replicated by HIV-1 proteins. Thus, efficient lentivirus pseudotyping can take place at the RNA level. Direct examination of the RNA contents of virus particles indicated that encapsidation of this heterologous RNA is efficient. Characterization of deletion mutants in the untranslated leader region of SIV RNA indicates that only a very short region at the 5' end of the SIV RNA is needed for packaging. Comparison of this region with the corresponding region of HIV-1 reveals that both are marked by secondary structures that are likely to be similar. Thus, it is likely that a similar higher-order RNA structure is required for encapsidation.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8474168      PMCID: PMC237590     

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  53 in total

1.  Tat trans-activates the human immunodeficiency virus through a nascent RNA target.

Authors:  B Berkhout; R H Silverman; K T Jeang
Journal:  Cell       Date:  1989-10-20       Impact factor: 41.582

2.  Construction of a retrovirus packaging mutant and its use to produce helper-free defective retrovirus.

Authors:  R Mann; R C Mulligan; D Baltimore
Journal:  Cell       Date:  1983-05       Impact factor: 41.582

Review 3.  Form and function of retroviral proviruses.

Authors:  H E Varmus
Journal:  Science       Date:  1982-05-21       Impact factor: 47.728

4.  Transfer of defective avian tumor virus genomes by a Rous sarcoma virus RNA packaging mutant.

Authors:  M Linial
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

5.  cis-Acting RNA packaging locus in the 115-nucleotide direct repeat of Rous sarcoma virus.

Authors:  J Sorge; W Ricci; S H Hughes
Journal:  J Virol       Date:  1983-12       Impact factor: 5.103

6.  Rous sarcoma virus p19 binds to specific double-stranded regions of viral RNA: effect of p19 on cleavage of viral RNA by RNase III.

Authors:  J P Leis; J McGinnis; R W Green
Journal:  Virology       Date:  1978-01       Impact factor: 3.616

7.  Specificity of RNA binding by the structural protein (p10) of Friend murine leukemia virus.

Authors:  J Nissen-Meyer; A K Abraham
Journal:  J Mol Biol       Date:  1980-09-05       Impact factor: 5.469

8.  Correlation of RNA binding affinity of avian oncornavirus p19 proteins with the extent of processing of virus genome RNA in cells.

Authors:  J P Leis; P Scheible; R E Smith
Journal:  J Virol       Date:  1980-09       Impact factor: 5.103

9.  Properties of the avian viral protein p12.

Authors:  K W Sykora; K Moelling
Journal:  J Gen Virol       Date:  1981-08       Impact factor: 3.891

10.  Encapsidation sequences for spleen necrosis virus, an avian retrovirus, are between the 5' long terminal repeat and the start of the gag gene.

Authors:  S Watanabe; H M Temin
Journal:  Proc Natl Acad Sci U S A       Date:  1982-10       Impact factor: 11.205

View more
  70 in total

1.  A lentivirus packaging system based on alternative RNA transport mechanisms to express helper and gene transfer vector RNAs and its use to study the requirement of accessory proteins for particle formation and gene delivery.

Authors:  N Srinivasakumar; F G Schuening
Journal:  J Virol       Date:  1999-11       Impact factor: 5.103

2.  Human immunodeficiency virus type 1 particles pseudotyped with envelope proteins that fuse at low pH no longer require Nef for optimal infectivity.

Authors:  N Chazal; G Singer; C Aiken; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

3.  The leader of the HIV-1 RNA genome forms a compactly folded tertiary structure.

Authors:  B Berkhout; J L van Wamel
Journal:  RNA       Date:  2000-02       Impact factor: 4.942

4.  Two alternating structures of the HIV-1 leader RNA.

Authors:  H Huthoff; B Berkhout
Journal:  RNA       Date:  2001-01       Impact factor: 4.942

5.  Human immunodeficiency virus types 1 and 2 differ in the predominant mechanism used for selection of genomic RNA for encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

6.  The effect of viral regulatory protein expression on gene delivery by human immunodeficiency virus type 1 vectors produced in stable packaging cell lines.

Authors:  N Srinivasakumar; N Chazal; C Helga-Maria; S Prasad; M L Hammarskjöld; D Rekosh
Journal:  J Virol       Date:  1997-08       Impact factor: 5.103

7.  Artificial tertiary motifs stabilize trans-cleaving hammerhead ribozymes under conditions of submillimolar divalent ions and high temperatures.

Authors:  Vanvimon Saksmerprome; Manami Roychowdhury-Saha; Sumedha Jayasena; Anastasia Khvorova; Donald H Burke
Journal:  RNA       Date:  2004-12       Impact factor: 4.942

8.  An extended stem-loop 1 is necessary for human immunodeficiency virus type 2 replication and affects genomic RNA encapsidation.

Authors:  Jean-Marc Lanchy; J Stephen Lodmell
Journal:  J Virol       Date:  2007-01-17       Impact factor: 5.103

9.  Mutational analysis of cis-acting packaging signals in human immunodeficiency virus type 1 RNA.

Authors:  J Luban; S P Goff
Journal:  J Virol       Date:  1994-06       Impact factor: 5.103

10.  Nonreciprocal packaging of human immunodeficiency virus type 1 and type 2 RNA: a possible role for the p2 domain of Gag in RNA encapsidation.

Authors:  J F Kaye; A M Lever
Journal:  J Virol       Date:  1998-07       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.